ArticleRSC advances2024
A new herbal extract carbon nanodot nanomedicine for anti-renal cell carcinoma through the PI3K/AKT signaling pathway.
Article in RSC advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
New Re carbon nanodots with narrow size distribution, good water solubility and high cell membrane permeability were prepared from a herbal extract. They exhibited high inhibitory effects on renal cancer A498 cells and renal cell carcinoma. They could stimulate the production of ROS, induce mitochondrial dysfunction, and accelerate the release of intracellular calcium ions in the A498 cells. Transcriptomic tests were performed on A498 cells after administration, and the results were analyzed by qPCR and immunofluorescence. The results suggested that the Re carbon nanodots could downregulate the abnormally activated PI3K/AKT signaling pathway and perform cell cycle arrest in the S phase along with the inhibition of cell proliferation. Finally, in conjunction with the abnormal mitochondrial function, the Re carbon nanodots could ultimately promote the apoptosis of the A498 cells.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.